Penile cancer: Clinical Practice Guidelines in Oncology

Autor: Pe, Clark, Pe, Spiess, Agarwal N, Mc, Biagioli, Ma, Eisenberger, Re, Greenberg, Hw, Herr, Brant Inman, Da, Kuban, Tm, Kuzel, Sm, Lele, Michalski J, Pagliaro L, Sk, Pal, Patterson A, Er, Plimack, Ks, Pohar, Mp, Porter, Jp, Richie, Wj, Sexton, Wu, Shipley, Ej, Small, Dl, Trump, Wile G, Tg, Wilson, Dwyer M, Ho M, National Comprehensive Cancer Network

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN, vol 11, iss 5
Europe PubMed Central

Squamous cell carcinoma of the penis represents approximately 0.5% of all cancers among men in the United States and other developed countries. Although rare, it is associated with significant disfigurement, and only half of the patients survive beyo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::45f74b36421d90ce911e21a5393f1bde
https://escholarship.org/uc/item/53d840zs

A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree.

Autor: Cannon-Albright LA; Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84108, USA.; George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA., Teerlink CC; Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.; George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA., Stevens J; Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA., Huang FW; Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, Bakar Computational Health Sciences Institute, Institute for Human Genetics, University of California, San Francisco, CA 94143, USA., Sipeky C; Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku University Hospital, 20521 Turku, Finland.; UCB Pharma, Data & Translational Sciences, 1420 Braine l'Alleud, Belgium., Schleutker J; Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku University Hospital, 20521 Turku, Finland.; Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, 20521 Turku, Finland., Hernandez R; Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA., Facelli J; Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.; Center for Clinical and Translational Science, University of Utah School of Medicine, Salt Lake City, UT 84112, USA., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84108, USA.; Division of Oncology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA., Trump DL; Inova Schar Cancer Institute, Inova Health System, 8081 Innovation Park Drive, Fairfax, VA 22031, USA.; Department of Medicine and Cancer Center, University of Virginia, Charlottesville, VA 22903, USA.

Publikováno v: Cancers [Cancers (Basel)] 2021 May 15; Vol. 13 (10). Date of Electronic Publication: 2021 May 15.

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).

Autor: Bunch B; a Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Krishnan N; a Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Greenspan RD; a Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Ramakrishnan S; a Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Attwood K; b Department of Bioinformatics and BioStatistics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Yan L; b Department of Bioinformatics and BioStatistics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Qi Q; b Department of Bioinformatics and BioStatistics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Wang D; b Department of Bioinformatics and BioStatistics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Morrison C; c Department of Pathology, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Omilian A; c Department of Pathology, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Bshara W; c Department of Pathology, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Pili R; d Department of Medicine, Indiana University , Buffalo , USA., Trump DL; e Inova Schar Cancer Institute , Falls Church , VA , USA., Johnson C; a Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center , Buffalo , USA., Woloszynska A; a Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center , Buffalo , USA.

Publikováno v: Cell cycle (Georgetown, Tex.) [Cell Cycle] 2019 Sep; Vol. 18 (17), pp. 2055-2066. Date of Electronic Publication: 2019 Jul 18.

Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.

Autor: McDonnell SL; GrassrootsHealth, Encinitas, California, United States of America., Baggerly CA; GrassrootsHealth, Encinitas, California, United States of America., French CB; GrassrootsHealth, Encinitas, California, United States of America., Baggerly LL; GrassrootsHealth, Encinitas, California, United States of America., Garland CF; Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, United States of America., Gorham ED; Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, United States of America., Hollis BW; Medical University of South Carolina, Charleston, South Carolina, United States of America., Trump DL; Inova Schar Cancer Institute, Falls Church, Virginia, United States of America., Lappe JM; Department of Medicine, Creighton University, Omaha, Nebraska, United States of America.

Publikováno v: PloS one [PLoS One] 2018 Jun 15; Vol. 13 (6), pp. e0199265. Date of Electronic Publication: 2018 Jun 15 (Print Publication: 2018).

Vitamin D in prostate cancer.

Autor: Trump DL; Inova Schar Cancer Institute, Inova Health System, Fairfax, VA 22037, USA., Aragon-Ching JB; Inova Schar Cancer Institute, Inova Health System, Fairfax, VA 22037, USA.

Publikováno v: Asian journal of andrology [Asian J Androl] 2018 May-Jun; Vol. 20 (3), pp. 244-252.